Literature DB >> 16123774

Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia.

Adrienne C Lahti1, Martin A Weiler, Henry H Holcomb, Carol A Tamminga, William T Carpenter, Robert McMahon.   

Abstract

We report on the correlations between whole brain rCBF and the positive and negative symptoms of schizophrenia in two cohorts of patients who were scanned while free of antipsychotic medication. We hypothesized that positive symptoms would correlate with rCBF in limbic and paralimbic regions, and that negative symptoms would correlate with rCBF in frontal and parietal regions. Both cohorts of patients with schizophrenia (Cohort 1: n=32; Cohort 2: n=23) were scanned using PET with H(2)(15)O while free of antipsychotic medication for an average of 21 and 15 days, respectively. Both groups were scanned during a resting state. Using SPM99, we conducted pixel by pixel linear regression analyses between BPRS scores and whole brain rCBF. As hypothesized, positive symptoms correlated with rCBF in the anterior cingulate cortex (ACC) in a positive direction and with the hippocampus/parahippocampus in a negative direction in both patient groups. When the positive symptoms were further divided into disorganization and hallucination/delusion scores, similar positive correlations with ACC and negative correlations with hippocampus rCBF were found. In both cohorts, the disorganization scores correlated positively with rCBF in Broca's area. As expected, negative symptoms correlated inversely with rCBF in frontal and parietal regions. This study provides evidence that limbic dysfunction may underlie the production of positive symptoms. It suggests that abnormal function of Broca's area may add a specific language-related dimension to positive symptoms. This study also provides further support for an independent neurobiological substrate of negative symptoms distinct from positive symptoms. The involvement of both frontal and parietal regions is implicated in the pathophysiology of negative symptoms. Neuropsychopharmacology (2006) 31, 221-230. doi:10.1038/sj.npp.1300837; published online 3 August 2005.

Entities:  

Mesh:

Year:  2006        PMID: 16123774     DOI: 10.1038/sj.npp.1300837

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  62 in total

1.  Gestational methylazoxymethanol acetate administration alters proteomic and metabolomic markers of hippocampal glutamatergic transmission.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

2.  Multicenter study of brain volume abnormalities in children and adolescent-onset psychosis.

Authors:  Santiago Reig; Mara Parellada; Josefina Castro-Fornieles; Joost Janssen; Dolores Moreno; Inmaculada Baeza; Nuria Bargalló; Ana González-Pinto; Montserrat Graell; Felipe Ortuño; Soraya Otero; Celso Arango; Manuel Desco
Journal:  Schizophr Bull       Date:  2010-05-16       Impact factor: 9.306

3.  Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI.

Authors:  Amy Pinkham; James Loughead; Kosha Ruparel; Wen-Chau Wu; Eve Overton; Raquel Gur; Ruben Gur
Journal:  Psychiatry Res       Date:  2011-08-09       Impact factor: 3.222

Review 4.  Developmental pathology, dopamine, stress and schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Int J Dev Neurosci       Date:  2010-08-19       Impact factor: 2.457

5.  A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.

Authors:  Meredith A Reid; David M White; Nina V Kraguljac; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2015-12-21       Impact factor: 4.939

6.  Abnormal white matter connections between medial frontal regions predict symptoms in patients with first episode schizophrenia.

Authors:  Toshiyuki Ohtani; Sylvain Bouix; Amanda E Lyall; Taiga Hosokawa; Yukiko Saito; Eric Melonakos; Carl-Fredrik Westin; Larry J Seidman; Jill Goldstein; Raquelle Mesholam-Gately; Tracey Petryshen; Joanne Wojcik; Marek Kubicki
Journal:  Cortex       Date:  2015-06-06       Impact factor: 4.027

Review 7.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 8.  Neuroimaging biomarkers for early drug development in schizophrenia.

Authors:  Jason R Tregellas
Journal:  Biol Psychiatry       Date:  2013-10-04       Impact factor: 13.382

9.  An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia.

Authors:  Li Chen; Stephanie M Perez; Daniel J Lodge
Journal:  Dev Neurobiol       Date:  2014-03-03       Impact factor: 3.964

10.  Ketamine induced changes in regional cerebral blood flow, interregional connectivity patterns, and glutamate metabolism.

Authors:  James Edward Bryant; Michael Frölich; Steve Tran; Meredith Amanda Reid; Adrienne Carol Lahti; Nina Vanessa Kraguljac
Journal:  J Psychiatr Res       Date:  2019-07-27       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.